Open AccessA New Hydroxyethyl Starch: HES 130/0.4 Voluven®
Author(s) -
Baron Jean François
Publication year - 2000
Publication title -
transfusion alternatives in transfusion medicine
Language(s) - English
Resource type - Journals
eISSN - 1778-428X
pISSN - 1295-9022
DOI - 10.1111/j.1778-428x.2000.tb00028.x
Subject(s) - hydroxyethyl starch , hypovolemia , medicine , plasma volume , fresh frozen plasma , intravascular volume status , hetastarch , blood volume , sepsis , intensive care medicine , blood product , anesthesia , surgery , hemodynamics , platelet
SUMMARY Blood volume is a critical factor in ma in taining hemody namic equilibrium and tissue oxyge nation. In travascular volume is regulated very closely by means of several complex mechanisms, for which the onset of action varies widely. Insome situations, such as acute bleeding, sepsis or with the use of certain drugs, the body must withstand absolute or relative changes in blood volume that cannot be immediately compensated for by the regulatory mechanisms. In these situations, the main goal of volume therapy is to temporarily increase plasma volume until the body's own mechanisms can correct the hypovolemia. Treatment of hypovolemia has changed significantly in recent years. In the past, fresh frozen plasma (FFP) or its equivalent was long the volume expander most commonly used. Now, indications for FFP are limited to the correction of some hemostatic disorders. A by‐product of this legitimate change in practice was increased use of human albumin. Because of the financial consequences of this strategy, several consensus conferences have issued recommendations on the best indications for the use of various plasma volume expanders. Despite these recommendations, the choice of the appropriate agent in the treatment of hypovolemia has not yet been settled. The debate on crystalloid s versus colloids continues, besides a debate on the choice of colloid.